Inventage Lab Presents Phase 1 Results of Long-Acting CNS Injectables at AAN

Inventage Lab, a drug delivery platform company, announced on April 20 that it will participate as a poster presenter at the 2026 American Academy of Neurology (AAN 2026) Annual Meeting, where it will present key Phase 1 clinical trial results for two of its long-acting injectable pipeline candidates. AAN is a prestigious international academic conference in the field of neuroscience, where global pharmaceutical and biotech companies and researchers share the latest research findings.

At this conference, Inventage Lab will present the Phase 1 clinical trial results of IVL3003, a dementia treatment, and IVL3004, a drug and alcohol addiction treatment, both developed using its long-acting injectable manufacturing platform 'IVL-DrugFluidic®.' The company explained that this presentation demonstrates how its long-acting formulation platform technology is expanding into various central nervous system (CNS) disease areas.

According to the company, IVL3003, its dementia treatment, maintained stable blood drug concentrations for more than four weeks in healthy subjects, unlike daily oral medications. Additionally, the amount of drug exposure in the body increased proportionally with higher doses, showing predictable pharmacokinetic characteristics. The company also reported that the pharmacological response—specifically, the inhibition of acetylcholinesterase, a substance that causes dementia—was consistently observed in line with blood concentration, and that the level of inhibition was within a similar range to that seen in the repeated oral Aricept dosing group. This supports that the drug is acting as intended within the body.

Regarding IVL3004, the drug and alcohol addiction treatment, the company stated that in clinical trials with healthy subjects, there was no initial burst release, and the effective blood concentration was maintained at a level equivalent to existing long-acting formulations, while adverse effects appeared to be alleviated.

Inventage Lab said that through this presentation, it confirmed in clinical settings that its long-acting formulation technology can achieve consistent release control characteristics across various drugs, and expects that it will be able to suggest improvements in patient medication convenience and treatment persistence.

Juhui Kim, CEO of Inventage Lab, stated, "In all three pipeline clinical trials conducted so far, we have consistently observed stable blood drug concentrations and dose-proportional characteristics. The fact that the same results are repeated with drugs of different mechanisms proves that our platform is a technology that can be expanded into various areas, not limited to specific drugs."

This content was produced with the assistance of AI translation services.